Anupam

Sector: Specialty Chemicals  |  HQ: Surat, Gujarat, India  |  Founded: 1984  |  Employees: 2,200+

Listed as: NSE / BSE listed (ANURAS)  |  NSE / BSE  |  Ticker: ANURAS.NS

Company overview

Anupam Rasayan India Limited (NSE: ANURAS, BSE: 543275) is a leading Indian specialty chemicals manufacturer focused on custom synthesis and manufacturing of life sciences related specialty chemicals for global agrochemical and pharmaceutical customers. Founded in 1984 by Anand Desai and Dr Kiran C Patel in Surat, Gujarat, the company has built a multi-decade track record in specialty chemicals contract manufacturing, with particular strength in agrochemical intermediates and active ingredients, pharmaceutical intermediates, and select specialty performance chemicals. Listed on the NSE and BSE in March 2021 at an issue price of ₹555 per share, Anupam Rasayan has been a representative public market name in the Indian specialty chemicals contract manufacturing theme. The company operates six manufacturing facilities across Gujarat (Sachin, Jhagadia, Bhilad), with combined installed capacity of approximately 25,000 tonnes per annum across multi-purpose chemical reactors. Customer relationships include leading global agrochemical and pharmaceutical companies under long-term supply agreements with material confidentiality protection. The Indian specialty chemicals contract manufacturing theme has been one of the most prominent stock market investment themes in the post-COVID period as global agrochemical and pharmaceutical customers have diversified supply chains away from China toward India, supporting structural revenue and margin tailwinds for Anupam Rasayan and peers.

Financial performance and recent trajectory

Disclosed revenue (FY25): ₹1,400 crore (FY 2024-25 estimate).

12-month price trajectory

Monthly closes over the last 12 months. Source: Yahoo Finance.

Competitive position

Anupam Rasayan operates in the Indian specialty chemicals contract manufacturing segment that includes peers such as Navin Fluorine International (NSE listed, fluorochemicals specialist), SRF Limited (NSE listed, diversified specialty chemicals and packaging), Aarti Industries (NSE listed, dye intermediates and specialty), PI Industries (NSE listed, agrochemical CSM leader), Galaxy Surfactants (NSE listed, personal care surfactants), Vinati Organics (NSE listed, IBB and ATBS leader), Fine Organic Industries (NSE listed, oleochemicals and food additives), Atul Limited (NSE listed, dyes and specialty), Laxmi Organic (NSE listed, ethyl acetate and diketene derivatives), and Clean Science and Technology (NSE listed, performance chemicals). In agrochemical CSM specifically, PI Industries is the largest listed pure-play with revenue exceeding ₹7,000 crore, followed by Anupam Rasayan, Sumitomo Chemical India (NSE listed), Bayer CropScience, and Insecticides India. Anupam Rasayan's competitive moats are the multi-decade customer relationships in agrochemical CSM, the multi-step complex synthesis capability in fluorinated and chiral chemistry, the six-plant capacity footprint with redundancy and flexibility, and the long-term contracted revenue visibility from key customer agreements. The principal vulnerabilities are the customer concentration on a small number of large agrochemical customers, the cyclical agrochemical inventory de-stocking that affected the segment through CY23 and into early CY24, and competitive intensity from PI Industries' scale and Navin Fluorine's fluorochemical leadership.

Key risks

Customer concentration on small number of large agrochemical customers Cyclical agrochemical inventory de-stocking affecting volume visibility Competitive intensity from PI Industries and Navin Fluorine specialty chemicals

Outlook

Anupam Rasayan India was founded in 1984 in Surat, Gujarat by Anand Desai and Dr Kiran C Patel. The early operations focused on conventional dye intermediates and basic specialty chemistry. Over the following three decades, the company progressively shifted toward higher-value custom synthesis and manufacturing (CSM) for global agrochemical and pharmaceutical customers, building capability in multi-step synthesis, fluorinated chemistry, chiral chemistry, and difficult-to-handle reactive intermediates. The business is organised across two principal segments. The Life Sciences Specialty Chemicals segment (over 95 percent of revenue) includes agrochemical intermediates and active ingredients, pharmaceutical intermediates and KSMs (key starting materials), and select fine chemicals. Agrochemical customers (whose names are typically protected under confidentiality agreements but include leading global agrochemical companies) account for over 70 percent of revenue. The Polymer Additives, Pigment and Dye Intermediates, and Other Specialty segment includes the legacy and supplementary specialty chemicals. Manufacturing is anchored at six facilities across Gujarat. The Sachin facility in Surat is the historical flagship with multi-purpose reactors. The Jhagadia facility hosts the larger-scale newer reactor train and is the focus of recent capacity additions. The Bhilad facility serves additional product lines. Combined installed reactor capacity is approximately 25,000 tonnes per annum with the flexibility to handle multi-step synthesis, fluorinated chemistry, and chiral chemistry. R&D is anchored at the corporate technology centre with focus on process development, scale-up, and customer co-development. Customer engagement is principally direct enterprise sales through long-term supply agreements typically of 5 to 10 year duration with confidentiality protection. The agrochemical CSM business model is structured around the customer providing the chemistry definition and the manufacturer providing scale-up, process optimisation, regulatory documentation, and reliable supply against contracted volumes. Anupam Rasayan has disclosed long-term supply contracts with cumulative value over ₹8,000 crore over the contract horizons, which provides materially improved revenue visibility relative to the typical specialty chemicals business model. Financial trajectory has been growth-driven through the post-IPO period although cyclically affected by the FY24 agrochemical inventory de-stocking. Revenue grew from ₹810 crore in FY21 to ₹1,082 crore in FY22, ₹1,259 crore in FY23, ₹1,300 crore in FY24 (modest growth as the agrochemical de-stocking affected volumes), and approximately ₹1,400 crore in FY25 as the cycle recovered. EBITDA margin has tracked at 25 to 32 percent, materially above the broader specialty chemicals industry average reflecting the high-value-add CSM mix. The IPO in March 2021 raised approximately ₹760 crore at an issue price of ₹555 per share. Recent corporate development has included continued capacity expansion at Jhagadia, debottlenecking at Sachin, new product launches under existing customer contracts, and the announcement of additional long-term supply agreements with global customers. The post-IPO period has seen Anupam Rasayan establish itself as one of the representative listed names in the Indian specialty chemicals CSM theme. Strategy through 2025 to 2030 is anchored on four themes. First, capacity expansion to over 35,000 tonnes per annum reactor capacity by FY28, principally through brownfield additions at Jhagadia. Second, customer relationship deepening with the existing core customer base and selective new customer onboarding particularly in pharmaceutical CSM. Third, technology and chemistry capability expansion into more complex multi-step synthesis, electrochemistry, and continuous flow chemistry. Fourth, the structural China Plus One supply chain shift that has been the dominant theme for Indian specialty chemicals over the past five years and is expected to continue through FY30. The regulatory environment includes the Environment Protection Act 1986 and related rules for emissions and effluent compliance (specialty chemicals manufacturing is subject to comprehensive environmental compliance), the Hazardous Waste Management Rules 2016, the Manufacture, Storage and Import of Hazardous Chemicals Rules 1989 (MSIHC Rules), the Insecticides Act 1968 for agrochemical active ingredients, the Drugs and Cosmetics Act 1940 for pharmaceutical intermediates, the Bureau of Indian Standards specifications, and the Customs Tariff Act 1975 for raw material imports and product exports. The Goods and Services Tax framework treats specialty chemicals at varying rates depending on the specific product category. The Companies Act 2013 and SEBI LODR govern listed company disclosure. Risks include customer concentration on a small number of large agrochemical customers, the cyclical agrochemical industry inventory de-stocking that materially affected FY24 volumes, raw material cost volatility (particularly fluorinated chemistry inputs and select pharma intermediates), regulatory compliance complexity in specialty chemicals manufacturing, currency exposure on USD-denominated export contracts, and competitive intensity from PI Industries' scale and Navin Fluorine's fluorochemical leadership. Management quality is anchored by Anand Desai as Chairman and Managing Director with the broader management team. The board has independent directors as required under SEBI LODR. Statutory audit is conducted by KKC and Associates LLP. Disclosure has been comprehensive with detailed customer contract value commentary at the aggregate level while protecting individual customer confidentiality. ESG positioning is moderate to strong within the specialty chemicals segment. The agrochemical CSM business contributes to the broader global food security agenda through enabling agrochemical innovation that supports crop yield improvement. Manufacturing facilities are progressively shifting toward renewable energy procurement, water recycling, and zero liquid discharge configurations. The Jhagadia plant has been configured with advanced effluent treatment infrastructure. BRSR disclosure is filed under SEBI LODR.

KAMRIT point of view

Building or competing with Anupam?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the specialty chemicals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Anupam and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Anupam in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.